CLINICAL_TRIALS ClinicalTrials.gov record update

Reblozyl® (Luspatercept) Post-Marketing Surveillance in Korean Patients With Myelodysplastic Syndrome or Beta Thalassemia

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06073860
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:09.055198+00:00
Published At: 2024-11-06T00:00:00+00:00
Record Updated At: 2024-11-06
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Myelodysplastic Syndrome", "Beta Thalassemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-11-06"
protocolSection.identificationModule.nctId: "NCT06073860"
protocolSection.identificationModule.officialTitle: "Reblozyl\u00ae (Luspatercept) Post-Marketing Surveillance in Korean Patients With Myelodysplastic Syndrome or Beta Thalassemia"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: []
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.